Drug Development

Feliza Mirasol is the science editor for 

Articles

GSK's MAA is supported by an interim analyis of Phase III trials, which demonstrated significant progression-free survival benefit and positive overall survival trends from Blenrep combination therapies.

GSK’s Application Seeking Blenrep Combinations for Treating Multiple Myeloma Accepted by EMA

With this acquisition, AstraZeneca gets a Phase III therapeutic peptide candidate that adds to the company's rare disease pipeline.

AstraZeneca Completes Amolyt Pharma Acquisition and Boosts Rare Disease Pipeline

Johnson & Johnson gains NM26, a Phase II-ready bispecific antibody in development for atopic dermatitis, boosting its immune-mediated and inflammatory disease portfolio.

Johnson & Johnson Gains Bispecific Antibody with Completion of Numab Subsidiary Acquisition

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Weighing development costs/resources and performance benefits is essential.

Biobetter Development

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Roche voluntarily recalled Susvimo’s ocular implant, insertion tool, and initial fill kit when test results did not satisfy company standards.

Roche to Reintroduce nAMD Treatment in US After FDA Approves Updates

Other indications for which the Sanofi treatment has been approved include atopic dermatitis, asthma, and chronic rhinosinusitis.

EU Makes First-in-World Approval of Dupixent as Targeted Therapy for Uncontrolled COPD

LenioBio and Labscoop's new strategic partnership is aimed at increasing access to scalable cell-free protein synthesis technology across North America.

Cell-Free Protein Synthesis Technology to be Made More Accessible Through LenioBio and Labscoop Partnership

This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.

AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition. 

Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets

Krizia M. Karry, PhD, ishead of Global Technical Marketing, Pharma Solutions, BASF.

Brian Carlin is president and owner of Carlin Pharma Consulting LLC.

Nigel Langley, PhD, MBA, is global technical director at Gaylord Life Sciences and Immediate Past Chair, IPEC- Americas.

R. Christian Moreton, PhD, is vice-president of pharmaceutical sciences at Finnbrit Consulting and a member of Pharmaceutical Technology’s editorial advisory board.

David Schoneker is president, Black Diamond Regulatory Consulting, LLC

Katherine L. Ulman is president of KLU Consulting.

Joseph Zeleznik is technical product director, IMCD US

Key information is needed for excipients and their potential impact on continuous manufacturing processes.

APIs and Excipients